Therapeutic Drug Monitoring of Voriconazole: Unbound Concentration With Clinical Efficacy and Adverse Events
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280251352876 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Tiantian Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Voriconazole, Antifungal Agents, Drug Monitoring, Mycoses. Die Arbeit nennt 27 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Voriconazole is widely used for patients with fungal infections, but the correlations between the unbound concentration (C free ) of voriconazole in plasma and clinical outcomes remains unclear.
Objective
The aim of this study was to analyze the correlation between C free and clinical outcomes.
Methods
A retrospective analysis was conducted at the Second Hospital of Hebei Medical University from February 2021 to March 2024 (Shijiazhuang, China). Patients who received voriconazole with at least one measured concentration in our center were enrolled. Based on determined the C free of voriconazole, factors that might affect C free were analyzed in conjunction with patient characteristics, and the correlations between voriconazole C free and the clinical efficacy as well as AEs in patients were investigated.
Results
A total of 60 blood samples were collected from 56 patients. Voriconazole C free was positive correlation with creatinine, while negative correlation with creatinine clearance. The C free of patients in the clinical effective group was significantly higher than that in the clinical ineffective group, and the C free of patients in the group with AEs was significantly higher than that in the group without AEs ( P = 0.006, 0.025). Voriconazole C free (odds ratio [OR] = 2.617, 95% confidence interval [CI]:1.142-6.000, P = 0.023) and albumin level (OR = 1.085, 95% CI: 1.000-1.177, P = 0.050) were independent influencing factors of clinical efficacy, the receiver operating characteristic (ROC) cut off for C free and efficacy was 0.8 μg·mL −1 . Voriconazole C free (OR = 1.979, 95% CI: 1.008-3.888, P = 0.048) was an independent risk factor for AEs, the ROC cut off for C free and AEs was 1.2 μg·mL −1 . Conclusions and relevance: Voriconazole C free was positively correlated with clinical efficacy and the incidence of AEs in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
- College of Pharmacy, Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Tiantian Zhang
Zitieren
APA
Zhang, T., Qiu, Z., Chu, W., Li, W., Wu, X., Wang, Y., Zhai, Y., Zhang, W., & Zhang, Z. (2026). Therapeutic Drug Monitoring of Voriconazole: Unbound Concentration With Clinical Efficacy and Adverse Events. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251352876
Vancouver
Zhang T, Qiu Z, Chu W, Li W, Wu X, Wang Y, et al. Therapeutic Drug Monitoring of Voriconazole: Unbound Concentration With Clinical Efficacy and Adverse Events. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251352876
BibTeX
@article{Zhang2026,
author = {Zhang, Tiantian and Qiu, Zhicong and Chu, Wenhao and Li, Wenli and Wu, Xikun and Wang, Yuxin and Zhai, Yishuo and Zhang, Wei and Zhang, Zhiqing},
title = {Therapeutic Drug Monitoring of Voriconazole: Unbound Concentration With Clinical Efficacy and Adverse Events},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280251352876}
}
EUVIMED